The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer

Annals of Oncology

Volumn 7, Issue 3, 1996, Pages 245-250

  Marini, G ^b   Murray, S ^b   Goldhirsch, A ^a   Gelber, R D ^b   Castiglione Gertsch, M ^b   Price, K N ^b   Tattersall, M H N ^b   Rudenstam, C M ^b   Collins, J ^b   Lindtner, J ^b   Cavalli, F ^b   Cortes Funes H ^b   Gudgeon, A ^b   Forbes, J F ^b   Galligioni, E ^b   Coates, A S ^b   Senn, H J ^b  

^a Ospedale Civico Lugano   (Switzerland)

^b NONE

Author keywords

Adjuvant therapy; Breast cancer; CMF; Patterns of relapse; Prednisone; Secondary neoplasm

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; PREDNISONE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER;

EID: 9244240954     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010567     Document Type: Article

References (23)

1. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405-10.
2. Cooper RG. Combination chemotherapy in hormone resistant breast cancer. Proc Am Assoc Cancer Res 1969; 10: 15.
3. Henderson IC. Chemotherapy for metastatic disease. In Harris JR, Hellman S, Henderson IC, Kinne DW (eds): Breast Diseases. Second edition. Philadelphia: JB Lippincott Company 1991; 604-65.
4. Engelsman E, Klijn JGM, Rubens RD et al. 'Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: An EORTC Breast Cancer Co-operative Group phase III trial (10808). Eur J Cancer 1991; 27: 966-70.
5. Tannock IF, Boyd NF, DeBoer G et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377-87.
6. Weiss RB, Korzun AH, Tormey DC et al. Adjuvant chemotherapy for breast carcinoma using CMFVP versus CMF versus CMF-MER: The nine year results from patients with 1-3 axillary nodes. In Salmon SE (ed): Adjuvant Therapy of Cancer V. Orlando: Grime & Stratton 1987; 327-36.
7. Tormey DC. Clinical results III: Experience of randomized trials without surgical controls. In Senn HJ (ed): Adjuvant Chemotherapy of Breast Cancer. Recent Results in Cancer Research. Heidelberg: Springer Verlag 1984; 155-65.
8. Tormey DC, Gray R, Gilchrist K et al. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. Cancer 1990; 65: 200-6.
9. Ludwig Breast Cancer Study Group. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 1985; 45: 4454-9.
10. Meakin JW, Allt WEC, Beale FA et al. Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Can Med Assoc J 1979; 120: 1221-31.
11. Hayakawa T, Kanai N, Yamada R et al. Effect of steroid hormone on activation of Endoxan (cyclophosphamide). Biochem Pharmacol 1969; 18: 129-35.
12. Faber OK, Mouridsen HT. Cyclophosphamide activation and corticosteroids. N Engl J Med 1974; 291: 211.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457-81.
14. Greenwood M. Reports on Public Health and Medical Subjects. Vol. 33. The Natural Duration of Cancer. London: His Majesty's Stationery Office 1926; 1-26.
15. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B (Methodology) 1972; 34: 187-220.
16. Gray RJ, Tsiatis AA. A linear rank test for use when the main interest is in differences in cure rates. Biometrics 1989; 45: 899-904.
17. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley 1980; 169.
18. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of competing risks. Ann Stat 1988; 16: 1141-54.
19. Goldhirsch A, Gelber RD, Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: Patterns and prognoses. J Clin Oncol 1988; 6: 89-97.
20. Miller R. Simultaneous Statistical Inference. New York; McGrawHill 1966.
21. Antman K. Dose-intensive therapy in breast cancer. In Armitage JO, Antman KH (eds): High-Dose Cancer Therapy. Baltimore: Williams & Wilkins 1992; 701-18.
22. Dimitrov N, Anderson S, Fisher B et al. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer: Findings from NSABP B-22. Proc Am Soc Clin Oncol 1994; 13: 58.
23. Wood WC, Budman DR, Korzun AH et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253-9.